[S02DA03, antipyrine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Bendroflumethiazide.]
[J01GA01, streptomycin, Bendroflumethiazide may increase the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AD04, streptozocin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Streptozocin.]
[M04AX02, pegloticase, The therapeutic efficacy of Pegloticase can be decreased when used in combination with Bendroflumethiazide.]
[L04AA27, fingolimod, Bendroflumethiazide may increase the bradycardic activities of Fingolimod.]
[A02BX02, sucralfate, Bendroflumethiazide may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Bendroflumethiazide may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Bendroflumethiazide.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Bendroflumethiazide.]
[M04AB02, sulfinpyrazone, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Bendroflumethiazide.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Bendroflumethiazide.]
[M01AB02, sulindac, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulindac.]
[N05AL01, sulpiride, The risk or severity of orthostatic hypotension can be increased when Bendroflumethiazide is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Bendroflumethiazide.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Bendroflumethiazide.]
[M01AX04, apazone, The therapeutic efficacy of Azapropazone can be decreased when used in combination with Bendroflumethiazide.]
[L01BB02, mercaptopurine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Mercaptopurine.]
[N05CD07, temazepam, Bendroflumethiazide may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB02, teniposide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Bendroflumethiazide.]
[B01AE07, dabigatran etexilate, Bendroflumethiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BA03, testosterone, Bendroflumethiazide may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA02, tetracycline, Bendroflumethiazide may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AE05, lurasidone, Lurasidone may decrease the antihypertensive activities of Bendroflumethiazide.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Thalidomide.]
[P02CA02, thiabendazole, Bendroflumethiazide may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX41, eribulin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Eribulin.]
[R06AD03, thiethylperazine, Bendroflumethiazide may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AC01, thiotepa, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Tioguanine.]
[N05CA19, thiopental, The risk or severity of hypotension and orthostatic hypotension can be increased when Thiopental is combined with Bendroflumethiazide.]
[N05AB08, thioproperazine, Thioproperazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[N05AC02, thioridazine, Thioridazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[G04BE06, moxisylyte, Bendroflumethiazide may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Bendroflumethiazide may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Bendroflumethiazide may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, The therapeutic efficacy of Timolol can be increased when used in combination with Bendroflumethiazide.]
[P01AB02, tinidazole, Bendroflumethiazide may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, Bendroflumethiazide may increase the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Bendroflumethiazide.]
[M02AX02, tolazoline, The therapeutic efficacy of Tolazoline can be increased when used in combination with Bendroflumethiazide.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bendroflumethiazide.]
[M02AA21, tolmetin, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolmetin.]
[N02AX02, tramadol, Bendroflumethiazide may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Bendroflumethiazide.]
[N06AX05, trazodone, The risk or severity of hyponatremia can be increased when Trazodone is combined with Bendroflumethiazide.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of electrolyte imbalance can be increased when Triamcinolone is combined with Bendroflumethiazide.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Bendroflumethiazide.]
[N05CD05, triazolam, Bendroflumethiazide may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Trichlormethiazide can be increased when used in combination with Bendroflumethiazide.]
[A03AB12, mepenzolate, The serum concentration of Bendroflumethiazide can be increased when it is combined with Mepenzolate.]
[A16AX12, trientine, Bendroflumethiazide may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB06, trifluoperazine, Trifluoperazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[S01AD02, trifluridine, Bendroflumethiazide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA05, triflupromazine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Triflupromazine.]
[S01BA09, clobetasone, The risk or severity of electrolyte imbalance can be increased when Clobetasone is combined with Bendroflumethiazide.]
[S01BA10, alclometasone, The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Bendroflumethiazide.]
[D07AC02, fluclorolone, The risk or severity of electrolyte imbalance can be increased when Fluclorolone is combined with Bendroflumethiazide.]
[N04AA01, trihexyphenidyl, The serum concentration of Bendroflumethiazide can be increased when it is combined with Trihexyphenidyl.]
[R03BA07, mometasone, The risk or severity of electrolyte imbalance can be increased when Mometasone is combined with Bendroflumethiazide.]
[A03AA05, trimebutine, Bendroflumethiazide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01ED04, metipranolol, The therapeutic efficacy of Metipranolol can be increased when used in combination with Bendroflumethiazide.]
[N03AC02, trimethadione, Trimethadione may increase the bradycardic activities of Bendroflumethiazide.]
[C02BA01, trimethaphan, The therapeutic efficacy of Trimethaphan can be increased when used in combination with Bendroflumethiazide.]
[J01EA01, trimethoprim, Bendroflumethiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA06, trimipramine, Trimipramine may decrease the antihypertensive activities of Bendroflumethiazide.]
[A03BB01, butylscopolamine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Butylscopolamine.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Bendroflumethiazide.]
[C09CA09, azilsartan medoxomil, The therapeutic efficacy of Azilsartan medoxomil can be increased when used in combination with Bendroflumethiazide.]
[M03AA02, tubocurarine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Tubocurarine.]
[R03DX07, roflumilast, Bendroflumethiazide may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Bendroflumethiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AA14, oxyquinoline, Bendroflumethiazide may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Bendroflumethiazide.]
[B01AD04, urokinase, The therapeutic efficacy of Urokinase can be decreased when used in combination with Bendroflumethiazide.]
[S01AA28, vancomycin, Bendroflumethiazide may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX21, ezogabine, Bendroflumethiazide may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, Bendroflumethiazide may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC18, indacaterol, The risk or severity of hypokalemia can be increased when Indacaterol is combined with Bendroflumethiazide.]
[B01AC24, ticagrelor, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Bendroflumethiazide.]
[C08DA01, verapamil, Bendroflumethiazide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX09, viloxazine, Bendroflumethiazide may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CA01, vinblastine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Vinblastine.]
[C04AX07, vincamine, The therapeutic efficacy of Vincamine can be increased when used in combination with Bendroflumethiazide.]
[L01CA03, vindesine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Vindesine.]
[B03BA01, vitamin B12, Bendroflumethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, Bendroflumethiazide may increase the excretion rate of Warfarin which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Bendroflumethiazide.]
[C03BA10, xipamide, The therapeutic efficacy of Xipamide can be increased when used in combination with Bendroflumethiazide.]
[J05AF01, zidovudine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Zidovudine.]
[N05AF05, zuclopenthixol, Zuclopenthixol may decrease the antihypertensive activities of Bendroflumethiazide.]
[M05BA05, tiludronic acid, Bendroflumethiazide may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC02, icatibant, Bendroflumethiazide may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Bendroflumethiazide.]
[B01AE01, desirudin, The therapeutic efficacy of Lepirudin can be decreased when used in combination with Bendroflumethiazide.]
[A02BC04, rabeprazole, Bendroflumethiazide may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[H05BX03, doxercalciferol, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Doxercalciferol.]
[N05AE04, ziprasidone, Ziprasidone may increase the antihypertensive activities of Bendroflumethiazide.]
[V03AC02, deferiprone, Bendroflumethiazide may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA34, alemtuzumab, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Alemtuzumab.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Bendroflumethiazide which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Bendroflumethiazide.]
[G04BD07, tolterodine, Bendroflumethiazide may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Bendroflumethiazide may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, The therapeutic efficacy of Atenolol can be increased when used in combination with Bendroflumethiazide.]
[L03AB11, peginterferon alfa-2a, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Peginterferon alfa-2a.]
[A11CC03, alfacalcidol, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Alfacalcidol.]
[L01FA01, rituximab, Bendroflumethiazide may increase the hypotensive activities of Rituximab.]
[M03AC04, atracurium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Atracurium.]
[S01FA01, atropine, Atropine may decrease the antihypertensive activities of Bendroflumethiazide.]
[M01CB03, auranofin, Bendroflumethiazide may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB11, prednylidene, The risk or severity of electrolyte imbalance can be increased when Prednylidene is combined with Bendroflumethiazide.]
[B03XA04, peginesatide, Bendroflumethiazide may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Bendroflumethiazide may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Bendroflumethiazide may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Bendroflumethiazide may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DF01, aztreonam, Bendroflumethiazide may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE10, avanafil, Bendroflumethiazide may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Bendroflumethiazide.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Gemtuzumab ozogamicin.]
[A08AA11, lorcaserin, Bendroflumethiazide may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, Bendroflumethiazide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG02, carfilzomib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Carfilzomib.]
[L02BB04, enzalutamide, Bendroflumethiazide may increase the excretion rate of Enzalutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Linaclotide.]
[L01EA04, bosutinib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bosutinib.]
[B01AX01, defibrotide, The therapeutic efficacy of Defibrotide can be decreased when used in combination with Bendroflumethiazide.]
[C01CA18, octopamine, Octopamine may decrease the antihypertensive activities of Bendroflumethiazide.]
[H02AA01, aldosterone, The risk or severity of electrolyte imbalance can be increased when Aldosterone is combined with Bendroflumethiazide.]
[L01EX05, regorafenib, Bendroflumethiazide may increase the bradycardic activities of Regorafenib.]
[N05CA04, barbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Barbital is combined with Bendroflumethiazide.]
[C01AA01, acetyldigitoxin, Bendroflumethiazide may increase the hypokalemic activities of Acetyldigitoxin.]
[D02BA02, octinoxate, Bendroflumethiazide may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA09, bendamustine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bendamustine.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Bendroflumethiazide.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Bendroflumethiazide.]
[C08CA13, lercanidipine, The therapeutic efficacy of Lercanidipine can be increased when used in combination with Bendroflumethiazide.]
[N06DA02, donepezil, Bendroflumethiazide may increase the bradycardic activities of Donepezil.]
[L04AA29, tofacitinib, Bendroflumethiazide may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Bendroflumethiazide.]
[R06AC06, thonzylamine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Thonzylamine.]
[G04BD10, darifenacin, The serum concentration of Bendroflumethiazide can be increased when it is combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Bendroflumethiazide may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Bendroflumethiazide.]
[H01CB05, pasireotide, Bendroflumethiazide may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, Sildenafil may increase the antihypertensive activities of Bendroflumethiazide.]
[V08CA11, gadofosveset, Bendroflumethiazide may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA05, ponatinib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ponatinib.]
[B01AF02, apixaban, The therapeutic efficacy of Apixaban can be decreased when used in combination with Bendroflumethiazide.]
[A16AX08, teduglutide, Bendroflumethiazide may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX11, bencyclane, Bendroflumethiazide may increase the bradycardic activities of Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Bendroflumethiazide.]
[A16AX09, glycerol phenylbutyrate, Bendroflumethiazide may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Bendroflumethiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA10, benorilate, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Benorilate.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.]
[M04AB03, benzbromarone, The therapeutic efficacy of Benzbromarone can be decreased when used in combination with Bendroflumethiazide.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tegaserod.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin detemir.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Bendroflumethiazide.]
[L03AA12, ancestim, Bendroflumethiazide may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Bendroflumethiazide.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Everolimus.]
[N04AC01, benztropine, Bendroflumethiazide may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AX03, benzydamine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Benzydamine.]
[L01EE01, trametinib, Bendroflumethiazide may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Bendroflumethiazide may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX28, levomilnacipran, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Bendroflumethiazide.]
[C08EA02, bepridil, The therapeutic efficacy of Bepridil can be increased when used in combination with Bendroflumethiazide.]
[C02KX05, riociguat, The therapeutic efficacy of Riociguat can be increased when used in combination with Bendroflumethiazide.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Bendroflumethiazide.]
[C02KX04, macitentan, The therapeutic efficacy of Macitentan can be increased when used in combination with Bendroflumethiazide.]
[L01EL01, ibrutinib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ibrutinib.]
[N06AX26, vortioxetine, Bendroflumethiazide may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, Bendroflumethiazide may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP08, sofosbuvir, Bendroflumethiazide may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Bendroflumethiazide.]
[C01CA27, droxidopa, The risk or severity of hypokalemia can be increased when Droxidopa is combined with Bendroflumethiazide.]
[C07AB04, acebutolol, The therapeutic efficacy of Acebutolol can be increased when used in combination with Bendroflumethiazide.]
[N05CH03, tasimelteon, Bendroflumethiazide may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA32, apremilast, Bendroflumethiazide may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG02, formestane, Bendroflumethiazide may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA03, betamethasone, The risk or severity of electrolyte imbalance can be increased when Betamethasone is combined with Bendroflumethiazide.]
[S01ED02, betaxolol, The therapeutic efficacy of Betaxolol can be increased when used in combination with Bendroflumethiazide.]
[B01AE03, argatroban, The therapeutic efficacy of Argatroban can be decreased when used in combination with Bendroflumethiazide.]
[V03AB34, fomepizole, Bendroflumethiazide may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be increased when used in combination with Bendroflumethiazide.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Bendroflumethiazide.]
[L01ED02, ceritinib, Bendroflumethiazide may increase the bradycardic activities of Ceritinib.]
[B01AC26, vorapaxar, The therapeutic efficacy of Vorapaxar can be decreased when used in combination with Bendroflumethiazide.]
[A03BA03, hyoscyamine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Hyoscyamine.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Bendroflumethiazide.]
[L01XH04, belinostat, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Belinostat.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Bendroflumethiazide.]
[R03AC19, olodaterol, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Bendroflumethiazide.]
[L03AB13, peginterferon beta-1a, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Bendroflumethiazide may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EE02, unoprostone, The therapeutic efficacy of Unoprostone can be increased when used in combination with Bendroflumethiazide.]
[D11AA01, glycopyrronium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Glycopyrronium.]
[V08AA04, iothalamic acid, Bendroflumethiazide may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA04, acepromazine, Acepromazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Phenolphthalein.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Bendroflumethiazide.]
[A06AH03, naloxegol, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naloxegol.]
[L01BC08, decitabine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Decitabine.]
[N04AA02, biperiden, The serum concentration of Bendroflumethiazide can be increased when it is combined with Biperiden.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bisacodyl.]
[L01FX07, blinatumomab, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Olaparib.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be decreased when used in combination with Bendroflumethiazide.]
[B01AF03, edoxaban, Bendroflumethiazide may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L01EF01, palbociclib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Palbociclib.]
[N02BE01, acetaminophen, Bendroflumethiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Bendroflumethiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AA09, difemerine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Difemerine.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be decreased when used in combination with Bendroflumethiazide.]
[C01EB17, ivabradine, The risk or severity of Cardiac Arrhythmia can be increased when Bendroflumethiazide is combined with Ivabradine.]
[A07DA06, eluxadoline, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Eluxadoline.]
[B01AC25, cangrelor, The therapeutic efficacy of Cangrelor can be decreased when used in combination with Bendroflumethiazide.]
[N05AX16, brexpiprazole, Brexpiprazole may decrease the antihypertensive activities of Bendroflumethiazide.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Bendroflumethiazide.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Magnesium peroxide.]
[N05AX15, cariprazine, Cariprazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Bendroflumethiazide.]
[M02AA25, aceclofenac, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Acemetacin.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin degludec.]
[V03AB37, idarucizumab, Bendroflumethiazide may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CX01, trabectedin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Trabectedin.]
[L01XG03, ixazomib, Bendroflumethiazide may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, The therapeutic efficacy of Selexipag can be increased when used in combination with Bendroflumethiazide.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bendroflumethiazide.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Bendroflumethiazide.]
[M04AB05, lesinurad, The therapeutic efficacy of Lesinurad can be decreased when used in combination with Bendroflumethiazide.]
[N05CA05, aprobarbital, The serum concentration of Bendroflumethiazide can be increased when it is combined with Aprobarbital.]
[M01AE16, alminoprofen, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Alminoprofen.]
[N03AX23, brivaracetam, Bendroflumethiazide may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA08, bromazepam, Bendroflumethiazide may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Bendroflumethiazide.]
[A02AD05, aluminum magnesium silicate, Bendroflumethiazide may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC11, amcinonide, The risk or severity of electrolyte imbalance can be increased when Amcinonide is combined with Bendroflumethiazide.]
[R06AB01, brompheniramine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Brompheniramine.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Bendroflumethiazide.]
[C08CA01, amlodipine, The therapeutic efficacy of Amlodipine can be increased when used in combination with Bendroflumethiazide.]
[C03CA02, bumetanide, Bendroflumethiazide may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Bendroflumethiazide.]
[C07AA19, bupranolol, The therapeutic efficacy of Bupranolol can be increased when used in combination with Bendroflumethiazide.]
[N07BC01, buprenorphine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Buprenorphine.]
[N05BE01, buspirone, Bendroflumethiazide may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AB01, busulfan, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Busulfan.]
[L01XX27, arsenic trioxide, Bendroflumethiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DA03, rivastigmine, Bendroflumethiazide may increase the bradycardic activities of Rivastigmine.]
[M02AA03, clofezone, Bendroflumethiazide may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Butorphanol.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Plecanatide.]
[A07EC04, balsalazide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypokalemia can be increased when Bambuterol is combined with Bendroflumethiazide.]
[A06AH05, naldemedine, Bendroflumethiazide may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Bendroflumethiazide may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, Bendroflumethiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA07, benazepril, The therapeutic efficacy of Benazepril can be increased when used in combination with Bendroflumethiazide.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Bendroflumethiazide.]
[H05BX05, calcifediol, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Calcifediol.]
[D05AX03, calcitriol, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Calcitriol.]
[A12AA04, calcium carbonate, Bendroflumethiazide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.]
[P01CA02, benznidazole, Bendroflumethiazide may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BA03, calcium chloride, Bendroflumethiazide may decrease the excretion rate of Calcium chloride which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Bendroflumethiazide.]
[J05AF06, abacavir, Bendroflumethiazide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[D11AX03, calcium gluconate, Bendroflumethiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.]
[N07XX13, valbenazine, Bendroflumethiazide may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A12AA01, calcium phosphate, Bendroflumethiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Bendroflumethiazide.]
[J01MA23, delafloxacin, Bendroflumethiazide may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF04, betrixaban, The therapeutic efficacy of Betrixaban can be decreased when used in combination with Bendroflumethiazide.]
[L01BC06, capecitabine, Bendroflumethiazide may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XH01, vorinostat, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Bisoprolol can be increased when used in combination with Bendroflumethiazide.]
[R03AC17, bitolterol, The risk or severity of hypokalemia can be increased when Bitolterol is combined with Bendroflumethiazide.]
[C07AA17, bopindolol, Bendroflumethiazide may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Bornaprine.]
[L01BA03, raltitrexed, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Raltitrexed.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nesiritide.]
[R03BA02, budesonide, The risk or severity of electrolyte imbalance can be increased when Budesonide is combined with Bendroflumethiazide.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Bendroflumethiazide.]
[M01AB07, bumadizone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bumadizone.]
[N05CA03, butobarbital, The serum concentration of Bendroflumethiazide can be increased when it is combined with Butobarbital.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Bendroflumethiazide.]
[C01AA02, acetyldigoxins, Bendroflumethiazide may increase the hypokalemic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Bendroflumethiazide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Bendroflumethiazide.]
[R06AX18, acrivastine, Bendroflumethiazide may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, The therapeutic efficacy of Captopril can be increased when used in combination with Bendroflumethiazide.]
[L02BB05, apalutamide, Bendroflumethiazide may increase the excretion rate of Apalutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, Bendroflumethiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level.]
[A03AA03, camylofine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Camylofin.]
[L03AB06, interferon alfa-n1, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The therapeutic efficacy of Carvedilol can be increased when used in combination with Bendroflumethiazide.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Bendroflumethiazide.]
[N03AX24, cannabidiol, Cannabidiol may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AA37, baricitinib, Bendroflumethiazide may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD14, ceftibuten, Bendroflumethiazide may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.]
[J01GB14, plazomicin, Bendroflumethiazide may increase the excretion rate of Plazomicin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB08, celiprolol, The therapeutic efficacy of Celiprolol can be increased when used in combination with Bendroflumethiazide.]
[A16AX14, migalastat, Bendroflumethiazide may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, Bendroflumethiazide may increase the excretion rate of Stiripentol which could result in a lower serum level and potentially a reduction in efficacy.]
[S01GX12, cetirizine, Bendroflumethiazide may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Bendroflumethiazide.]
[N01BA04, chloroprocaine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Chloroprocaine.]
[D08AE05, chloroxylenol, Bendroflumethiazide may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA06, chlorphenoxamine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lornoxicam.]
[R03BB08, revefenacin, The serum concentration of Bendroflumethiazide can be increased when it is combined with Revefenacin.]
[L01AD01, carmustine, Bendroflumethiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Prucalopride.]
[C09AA08, cilazapril, The therapeutic efficacy of Cilazapril can be increased when used in combination with Bendroflumethiazide.]
[B01AC23, cilostazol, Bendroflumethiazide may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Bendroflumethiazide.]
[S01ED05, carteolol, The therapeutic efficacy of Carteolol can be increased when used in combination with Bendroflumethiazide.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Bendroflumethiazide.]
[N06BA14, solriamfetol, Bendroflumethiazide may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA09, clobazam, Bendroflumethiazide may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AB21, clocortolone, The risk or severity of electrolyte imbalance can be increased when Clocortolone is combined with Bendroflumethiazide.]
[H02AB14, cloprednol, The risk or severity of electrolyte imbalance can be increased when Cloprednol is combined with Bendroflumethiazide.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Castor oil.]
[V03AE07, calcium acetate, Bendroflumethiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.]
[C09CA06, candesartan, The therapeutic efficacy of Candesartan can be increased when used in combination with Bendroflumethiazide.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of electrolyte imbalance can be increased when Cortivazol is combined with Bendroflumethiazide.]
[J01DC04, cefaclor, Bendroflumethiazide may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB05, cefadroxil, Bendroflumethiazide may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC05, cefotetan, Bendroflumethiazide may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD02, ceftazidime, Bendroflumethiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BX03, cicletanine, The therapeutic efficacy of Cicletanine can be increased when used in combination with Bendroflumethiazide.]
[J01DD04, ceftriaxone, Bendroflumethiazide may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX11, pitolisant, Bendroflumethiazide may increase the excretion rate of Pitolisant which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Cyclothiazide can be increased when used in combination with Bendroflumethiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Bendroflumethiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin pork.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dantron.]
[J01XX09, daptomycin, Bendroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, Bendroflumethiazide may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB09, cephradine, Bendroflumethiazide may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB13, deflazacort, The risk or severity of electrolyte imbalance can be increased when Deflazacort is combined with Bendroflumethiazide.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Trastuzumab emtansine.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Bendroflumethiazide.]
[M09AX08, golodirsen, Bendroflumethiazide may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA12, dexpanthenol, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Dexpanthenol.]
[N02AX03, dezocine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Dezocine.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Bendroflumethiazide.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Bendroflumethiazide.]
[R02AA03, dichlorobenzyl alcohol, Bendroflumethiazide may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, Bendroflumethiazide may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC19, difluprednate, The risk or severity of electrolyte imbalance can be increased when Difluprednate is combined with Bendroflumethiazide.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may decrease the antihypertensive activities of Bendroflumethiazide.]
[M01AH02, rofecoxib, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bexarotene.]
[C08CA16, clevidipine, Bendroflumethiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD07, dronedarone, Dronedarone may decrease the antihypertensive activities of Bendroflumethiazide.]
[S01EA02, dipivefrin, The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Bendroflumethiazide.]
[L01AA02, chlorambucil, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Chloramphenicol.]
[C02AA06, methoserpidine, The therapeutic efficacy of Methoserpidine can be increased when used in combination with Bendroflumethiazide.]
[A03AA08, dihexyverine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Dihexyverine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Opicapone.]
[C01CA14, dopexamine, Dopexamine may decrease the antihypertensive activities of Bendroflumethiazide.]
[D07XB03, fluprednidene, The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Bendroflumethiazide.]
[G04BD09, trospium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Trospium.]
[M01AC04, droxicam, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Droxicam.]
[V08CA05, mangafodipir, Bendroflumethiazide may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Bendroflumethiazide.]
[S01BA14, loteprednol, The risk or severity of electrolyte imbalance can be increased when Loteprednol is combined with Bendroflumethiazide.]
[B01AE02, lepirudin, The therapeutic efficacy of Lepirudin can be decreased when used in combination with Bendroflumethiazide.]
[M02AA27, dexketoprofen, The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bendroflumethiazide.]
[C08CA17, levamlodipine, The therapeutic efficacy of Levamlodipine can be increased when used in combination with Bendroflumethiazide.]
[N02AX07, oliceridine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Bendroflumethiazide may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Chlorothiazide can be increased when used in combination with Bendroflumethiazide.]
[N05AA01, chlorpromazine, Bendroflumethiazide may increase the excretion rate of Chlorpromazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bendroflumethiazide.]
[N05AF03, chlorprothixene, The serum concentration of Bendroflumethiazide can be increased when it is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Chlorthalidone can be increased when used in combination with Bendroflumethiazide.]
[M03BB03, chlorzoxazone, Bendroflumethiazide may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[A11CC05, cholecalciferol, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Cholecalciferol.]
[N02BA07, ethenzamide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, Bendroflumethiazide may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX18, vinpocetine, Bendroflumethiazide may increase the bradycardic activities of Vinpocetine.]
[M01AB08, etodolac, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etofenamate.]
[L01BB05, fludarabine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Fludarabine.]
[M01AX25, chondroitin sulfates, Bendroflumethiazide may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Bendroflumethiazide.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Vericiguat.]
[M01AE05, fenbufen, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be increased when used in combination with Bendroflumethiazide.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Bendroflumethiazide.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Bendroflumethiazide.]
[J01DD15, cefdinir, Bendroflumethiazide may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA03, flunisolide, The risk or severity of electrolyte imbalance can be increased when Flunisolide is combined with Bendroflumethiazide.]
[S02BA08, fluocinolone acetonide, The risk or severity of electrolyte imbalance can be increased when Fluocinolone acetonide is combined with Bendroflumethiazide.]
[N02BG07, flupirtine, Bendroflumethiazide may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC15, formoterol, The risk or severity of hypokalemia can be increased when Formoterol is combined with Bendroflumethiazide.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Bendroflumethiazide.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Bendroflumethiazide.]
[L03AB10, peginterferon alfa-2b, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, The therapeutic efficacy of Dasiglucagon can be increased when used in combination with Bendroflumethiazide.]
[A02BA01, cimetidine, Bendroflumethiazide may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA04, gadoteridol, Bendroflumethiazide may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, Bendroflumethiazide may increase the bradycardic activities of Cinnarizine.]
[S03AA07, ciprofloxacin, Bendroflumethiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XA01, cisplatin, Bendroflumethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB04, citalopram, The risk or severity of hyponatremia can be increased when Citalopram is combined with Bendroflumethiazide.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Fexinidazole.]
[V09AB03, ioflupane I-123, Bendroflumethiazide may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Bendroflumethiazide may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX06, florbetaben f-18, Bendroflumethiazide may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mefenamic acid.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Bendroflumethiazide.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Bendroflumethiazide.]
[R03CC13, clenbuterol, The risk or severity of hypokalemia can be increased when Clenbuterol is combined with Bendroflumethiazide.]
[A12AA02, calcium glubionate, Bendroflumethiazide may decrease the excretion rate of Calcium glubionate anhydrous which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ropeginterferon alfa-2b.]
[D07AD01, clobetasol, The risk or severity of electrolyte imbalance can be increased when Clobetasol is combined with Bendroflumethiazide.]
[B01AD11, tenecteplase, The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Bendroflumethiazide.]
[N01BB10, levobupivacaine, Bendroflumethiazide may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA04, clomipramine, Bendroflumethiazide may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AE01, clonazepam, Bendroflumethiazide may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Bendroflumethiazide.]
[J05AH02, oseltamivir, Bendroflumethiazide may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Bendroflumethiazide.]
[N05AH02, clozapine, Bendroflumethiazide may increase the excretion rate of Clozapine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Bendroflumethiazide.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Bendroflumethiazide.]
[D07AC12, halometasone, The risk or severity of electrolyte imbalance can be increased when Halometasone is combined with Bendroflumethiazide.]
[S02DA02, cocaine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Cocaine.]
[C02KB01, metyrosine, The therapeutic efficacy of Metyrosine can be increased when used in combination with Bendroflumethiazide.]
[M01AX13, proquazone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Proquazone.]
[R05DA04, codeine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Codeine.]
[M03AC05, hexafluorenium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Hexafluronium.]
[M04AC01, colchicine, The therapeutic efficacy of Colchicine can be decreased when used in combination with Bendroflumethiazide.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AB10, hexocyclium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Homatropine methylbromide.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Bendroflumethiazide.]
[A04AA03, tropisetron, Bendroflumethiazide may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Bendroflumethiazide.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Bendroflumethiazide.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Bendroflumethiazide.]
[L01BB07, nelarabine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Nelarabine.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin glargine.]
[R03BA08, ciclesonide, The risk or severity of electrolyte imbalance can be increased when Ciclesonide is combined with Bendroflumethiazide.]
[B01AC10, indobufen, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indobufen.]
[R06AX27, desloratadine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Desloratadine.]
[J05AB14, valganciclovir, Bendroflumethiazide may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Bendroflumethiazide may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Bendroflumethiazide may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Bendroflumethiazide may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Bendroflumethiazide may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Bendroflumethiazide may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Valdecoxib.]
[C01AA06, lanatoside C, Bendroflumethiazide may increase the hypokalemic activities of Lanatoside C.]
[A03AX10, isometheptene, Isometheptene may decrease the antihypertensive activities of Bendroflumethiazide.]
[N02CC05, almotriptan, Bendroflumethiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Parecoxib.]
[B01AB12, bemiparin, The therapeutic efficacy of Bemiparin can be decreased when used in combination with Bendroflumethiazide.]
[S01AD03, acyclovir, Bendroflumethiazide may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA10, ketazolam, Bendroflumethiazide may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Kebuzone.]
[L01EA01, imatinib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Imatinib.]
[S01EE04, travoprost, The therapeutic efficacy of Travoprost can be increased when used in combination with Bendroflumethiazide.]
[S01EE03, bimatoprost, The therapeutic efficacy of Bimatoprost can be increased when used in combination with Bendroflumethiazide.]
[C08CA09, lacidipine, Bendroflumethiazide may increase the hypotensive activities of Lacidipine.]
[V03AF07, rasburicase, The therapeutic efficacy of Rasburicase can be decreased when used in combination with Bendroflumethiazide.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Lactitol.]
[N03AX09, lamotrigine, Bendroflumethiazide may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA03, cortisone, The risk or severity of electrolyte imbalance can be increased when Cortisone is combined with Bendroflumethiazide.]
[N07BC04, lofexidine, The therapeutic efficacy of Lofexidine can be increased when used in combination with Bendroflumethiazide.]
[M01AB09, lonazolac, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lonazolac.]
[M02AA31, loxoprofen, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Loxoprofen.]
[C09AA03, lisinopril, The therapeutic efficacy of Lisinopril can be increased when used in combination with Bendroflumethiazide.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Magnesium carbonate.]
[C08CA11, manidipine, The therapeutic efficacy of Manidipine can be increased when used in combination with Bendroflumethiazide.]
[A03AA04, mebeverine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Mebeverine.]
[S01BA08, medrysone, The risk or severity of electrolyte imbalance can be increased when Medrysone is combined with Bendroflumethiazide.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Bendroflumethiazide.]
[C07AA14, mepindolol, Bendroflumethiazide may increase the bradycardic activities of Mepindolol.]
[H02AB15, meprednisone, The risk or severity of electrolyte imbalance can be increased when Meprednisone is combined with Bendroflumethiazide.]
[J01DH02, meropenem, Bendroflumethiazide may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[N04AA03, methixene, The serum concentration of Bendroflumethiazide can be increased when it is combined with Metixene.]
[C04AX01, cyclandelate, Bendroflumethiazide may increase the bradycardic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the antihypertensive activities of Bendroflumethiazide.]
[C03DA04, eplerenone, The therapeutic efficacy of Eplerenone can be increased when used in combination with Bendroflumethiazide.]
[N05AD03, metylperon, Bendroflumethiazide may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Cyclopenthiazide can be increased when used in combination with Bendroflumethiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Bendroflumethiazide.]
[J05AF07, tenofovir disoproxil, Bendroflumethiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA01, cyclophosphamide, The risk or severity of granulocytopenia can be increased when Bendroflumethiazide is combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Bendroflumethiazide.]
[S01XA18, cyclosporine, The risk or severity of renal failure can be increased when Bendroflumethiazide is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Bendroflumethiazide.]
[R06AX02, cyproheptadine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Cyproheptadine.]
[C09AA13, moexipril, The therapeutic efficacy of Moexipril can be increased when used in combination with Bendroflumethiazide.]
[M02AA02, mofebutazone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Conivaptan.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be increased when used in combination with Bendroflumethiazide.]
[L01BC01, cytarabine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Cytarabine.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Bendroflumethiazide.]
[M01AH05, etoricoxib, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etoricoxib.]
[L01AX04, dacarbazine, Bendroflumethiazide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DA01, dactinomycin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Daunorubicin.]
[C02CC04, debrisoquin, The therapeutic efficacy of Debrisoquine can be increased when used in combination with Bendroflumethiazide.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nabilone.]
[M01AX01, nabumetone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nabumetone.]
[N07BB05, nalmefene, Bendroflumethiazide may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Potassium lactate.]
[C07AB12, nebivolol, The therapeutic efficacy of Nebivolol can be increased when used in combination with Bendroflumethiazide.]
[S01GX04, nedocromil, Bendroflumethiazide may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, The risk or severity of hyponatremia can be increased when Nefazodone is combined with Bendroflumethiazide.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Bendroflumethiazide.]
[L02BB02, nilutamide, Bendroflumethiazide may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Bendroflumethiazide.]
[M03AC11, cisatracurium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Cisatracurium.]
[C01CA05, norfenefrine, Norfenefrine may decrease the antihypertensive activities of Bendroflumethiazide.]
[R05DA06, normethadone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Bendroflumethiazide may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB10, escitalopram, The risk or severity of hyponatremia can be increased when Escitalopram is combined with Bendroflumethiazide.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Bendroflumethiazide.]
[A07EC03, olsalazine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, Bendroflumethiazide may increase the excretion rate of Desipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AA07, deslanoside, Bendroflumethiazide may increase the hypokalemic activities of Deslanoside.]
[H01BA02, desmopressin, Bendroflumethiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA11, desonide, The risk or severity of electrolyte imbalance can be increased when Desonide is combined with Bendroflumethiazide.]
[D07XC02, desoximetasone, The risk or severity of electrolyte imbalance can be increased when Desoximetasone is combined with Bendroflumethiazide.]
[V04CH02, indigo carmine, Bendroflumethiazide may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA03, desoxycorticosterone, The risk or severity of electrolyte imbalance can be increased when Desoxycortone is combined with Bendroflumethiazide.]
[J01DH03, ertapenem, Bendroflumethiazide may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The therapeutic efficacy of Aliskiren can be increased when used in combination with Bendroflumethiazide.]
[L01XA03, oxaliplatin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of hyponatremia can be increased when Bendroflumethiazide is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The risk or severity of electrolyte imbalance can be increased when Dexamethasone is combined with Bendroflumethiazide.]
[N04AA08, dexetimide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Dexetimide.]
[G04BD04, oxybutynin, The serum concentration of Bendroflumethiazide can be increased when it is combined with Oxybutynin.]
[A03AA01, oxyphencyclimine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Oxyphencyclimine.]
[N06BA02, dextroamphetamine, Bendroflumethiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA09, dextromethorphan, The serum concentration of Bendroflumethiazide can be increased when it is combined with Dextromethorphan.]
[N02AC01, dextromoramide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Bendroflumethiazide.]
[N07BC06, heroin, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Bendroflumethiazide may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Bendroflumethiazide may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Bendroflumethiazide may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Bendroflumethiazide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Bendroflumethiazide.]
[R05DA08, pholcodine, Bendroflumethiazide may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Diclofenamide.]
[S01BC03, diclofenac, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diclofenac.]
[A03AA07, dicyclomine, Bendroflumethiazide may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF02, didanosine, Bendroflumethiazide may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, The therapeutic efficacy of Pinacidil can be increased when used in combination with Bendroflumethiazide.]
[A03AX04, pinaverium, Bendroflumethiazide may increase the bradycardic activities of Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bendroflumethiazide.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Pipamperone.]
[A03AB14, pipenzolate, The serum concentration of Bendroflumethiazide can be increased when it is combined with Pipenzolate.]
[L01DC04, ixabepilone, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ixabepilone.]
[R03CC07, pirbuterol, The risk or severity of hypokalemia can be increased when Pirbuterol is combined with Bendroflumethiazide.]
[A08AA03, diethylpropion, Diethylpropion may decrease the antihypertensive activities of Bendroflumethiazide.]
[C08CA03, isradipine, The therapeutic efficacy of Isradipine can be increased when used in combination with Bendroflumethiazide.]
[D07XC04, diflucortolone, The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Bendroflumethiazide.]
[A03AB11, poldine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Poldine.]
[N02BA11, diflunisal, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diflunisal.]
[C01AA04, digitoxin, Bendroflumethiazide may increase the hypokalemic activities of Digitoxin.]
[C01AA05, digoxin, Bendroflumethiazide may increase the hypokalemic activities of Digoxin.]
[C02DB01, dihydralazine, The therapeutic efficacy of Dihydralazine can be increased when used in combination with Bendroflumethiazide.]
[C04AE04, dihydroergocristine, Dihydroergocristine may decrease the antihypertensive activities of Bendroflumethiazide.]
[N02CA01, dihydroergotamine, Dihydroergotamine may decrease the antihypertensive activities of Bendroflumethiazide.]
[N02AA03, hydromorphone, Bendroflumethiazide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Bendroflumethiazide may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[A11CC02, dihydrotachysterol, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Dihydrotachysterol.]
[B01AC21, treprostinil, The therapeutic efficacy of Treprostinil can be increased when used in combination with Bendroflumethiazide.]
[H03BC01, potassium perchlorate, Bendroflumethiazide may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Bendroflumethiazide may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC18, prednicarbate, The risk or severity of electrolyte imbalance can be increased when Prednicarbate is combined with Bendroflumethiazide.]
[C08DB01, diltiazem, The therapeutic efficacy of Diltiazem can be increased when used in combination with Bendroflumethiazide.]
[V03AB09, dimercaprol, Bendroflumethiazide may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB03, dimethindene, The serum concentration of Bendroflumethiazide can be increased when it is combined with Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypokalemia can be increased when Procaterol is combined with Bendroflumethiazide.]
[M02AX03, dimethyl sulfoxide, Bendroflumethiazide may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Proglumetacin.]
[R06AA02, diphenhydramine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, The therapeutic efficacy of Quinapril can be increased when used in combination with Bendroflumethiazide.]
[B01AC07, dipyridamole, Dipyridamole may increase the antihypertensive activities of Bendroflumethiazide.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Bendroflumethiazide.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Bendroflumethiazide.]
[C09AA05, ramipril, The therapeutic efficacy of Ramipril can be increased when used in combination with Bendroflumethiazide.]
[S01XA23, sirolimus, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Sirolimus.]
[R03CC14, reproterol, Reproterol may decrease the antihypertensive activities of Bendroflumethiazide.]
[S01AX06, resorcinol, Bendroflumethiazide may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Bendroflumethiazide.]
[N05AX08, risperidone, Bendroflumethiazide may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Bendroflumethiazide may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Bendroflumethiazide may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Bendroflumethiazide.]
[L01XG01, bortezomib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bortezomib.]
[G04BE08, tadalafil, The therapeutic efficacy of Tadalafil can be increased when used in combination with Bendroflumethiazide.]
[S01BC05, ketorolac, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, The therapeutic efficacy of Ambrisentan can be increased when used in combination with Bendroflumethiazide.]
[C01EB18, ranolazine, Bendroflumethiazide may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA06, salsalate, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Bendroflumethiazide.]
[H05BA01, salmon calcitonin, Bendroflumethiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, The risk or severity of hypokalemia can be increased when Dobutamine is combined with Bendroflumethiazide.]
[C01CA04, dopamine, Bendroflumethiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA16, dothiepin, Dosulepin may decrease the antihypertensive activities of Bendroflumethiazide.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Bendroflumethiazide.]
[N06AA12, doxepin, Bendroflumethiazide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sennosides.]
[L01DB01, doxorubicin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Doxorubicin.]
[J01AA02, doxycycline, Bendroflumethiazide may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA09, doxylamine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Doxylamine.]
[N06AB06, sertraline, The risk or severity of hyponatremia can be increased when Sertraline is combined with Bendroflumethiazide.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Bendroflumethiazide.]
[N05AD08, droperidol, Droperidol may decrease the antihypertensive activities of Bendroflumethiazide.]
[A08AA10, sibutramine, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Bendroflumethiazide.]
[V03AG05, sodium phosphate, Bendroflumethiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sodium sulfate.]
[C09AA11, spirapril, The therapeutic efficacy of Spirapril can be increased when used in combination with Bendroflumethiazide.]
[R03DA01, dyphylline, Bendroflumethiazide may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Bendroflumethiazide may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX07, edrophonium, Bendroflumethiazide may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, The therapeutic efficacy of Talinolol can be increased when used in combination with Bendroflumethiazide.]
[H01AA01, corticotropin, The risk or severity of electrolyte imbalance can be increased when Corticotropin is combined with Bendroflumethiazide.]
[L01AX03, temozolomide, Bendroflumethiazide may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tenoxicam.]
[G04CA03, terazosin, The therapeutic efficacy of Terazosin can be increased when used in combination with Bendroflumethiazide.]
[G04BD05, terodiline, Bendroflumethiazide may increase the bradycardic activities of Terodiline.]
[C07AA16, tertatolol, Bendroflumethiazide may increase the bradycardic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, Tetryzoline may decrease the antihypertensive activities of Bendroflumethiazide.]
[M04AA02, tisopurine, The therapeutic efficacy of Tisopurine can be decreased when used in combination with Bendroflumethiazide.]
[G04BD01, emepronium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Emepronium.]
[N06AX14, tianeptine, Tianeptine may decrease the antihypertensive activities of Bendroflumethiazide.]
[C09AA02, enalapril, The therapeutic efficacy of Enalapril can be increased when used in combination with Bendroflumethiazide.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Bendroflumethiazide.]
[N06BA09, atomoxetine, Bendroflumethiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, The risk or severity of hypokalemia can be increased when Bendroflumethiazide is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Toremifene.]
[C03CA04, torsemide, The therapeutic efficacy of Torasemide can be increased when used in combination with Bendroflumethiazide.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Bendroflumethiazide.]
[C09AA10, trandolapril, The therapeutic efficacy of Trandolapril can be increased when used in combination with Bendroflumethiazide.]
[N05CC01, chloral hydrate, Bendroflumethiazide may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB08, tridihexethyl, The serum concentration of Bendroflumethiazide can be increased when it is combined with Tridihexethyl.]
[B01AC18, triflusal, The therapeutic efficacy of Triflusal can be decreased when used in combination with Bendroflumethiazide.]
[H02CA01, trilostane, The risk or severity of electrolyte imbalance can be increased when Trilostane is combined with Bendroflumethiazide.]
[N04AA12, tropatepine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Tropatepine.]
[C05CA04, troxerutin, The therapeutic efficacy of Troxerutin can be decreased when used in combination with Bendroflumethiazide.]
[R03CC11, tulobuterol, Tulobuterol may decrease the antihypertensive activities of Bendroflumethiazide.]
[C02CA06, urapidil, The therapeutic efficacy of Urapidil can be increased when used in combination with Bendroflumethiazide.]
[L01CA04, vinorelbine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Vinorelbine.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Bendroflumethiazide.]
[N06AX16, venlafaxine, Bendroflumethiazide may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CX07, xamoterol, Xamoterol may decrease the antihypertensive activities of Bendroflumethiazide.]
[S01GA03, xylometazoline, Xylometazoline may decrease the antihypertensive activities of Bendroflumethiazide.]
[C08CA12, mepirodipine, Bendroflumethiazide may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, The risk or severity of hypokalemia can be increased when Epinephrine is combined with Bendroflumethiazide.]
[L01DB03, epirubicin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Epirubicin.]
[C09AA15, zofenopril, The therapeutic efficacy of Zofenopril can be increased when used in combination with Bendroflumethiazide.]
[M01AB04, zomepirac, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zomepirac.]
[N03AX15, zonisamide, Bendroflumethiazide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin glulisine.]
[B01AD03, anistreplase, The therapeutic efficacy of Anistreplase can be decreased when used in combination with Bendroflumethiazide.]
[L01XA02, carboplatin, Bendroflumethiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be increased when used in combination with Bendroflumethiazide.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Bendroflumethiazide.]
[A11CC01, ergocalciferol, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Ergocalciferol.]
[G02AB03, ergonovine, Ergometrine may decrease the antihypertensive activities of Bendroflumethiazide.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Bendroflumethiazide.]
[N02CA02, ergotamine, Ergotamine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L03AX05, pidotimod, Bendroflumethiazide may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD04, estazolam, Bendroflumethiazide may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Bendroflumethiazide may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, Bendroflumethiazide may increase the excretion rate of Estradiol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA57, estrogens, conjugated (USP), Bendroflumethiazide may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Bendroflumethiazide may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA09, fluticasone furoate, The risk or severity of electrolyte imbalance can be increased when Fluticasone furoate is combined with Bendroflumethiazide.]
[R03BA05, fluticasone, The risk or severity of electrolyte imbalance can be increased when Fluticasone is combined with Bendroflumethiazide.]
[V08CA03, gadodiamide, Bendroflumethiazide may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA15, gepefrine, Gepefrine may decrease the antihypertensive activities of Bendroflumethiazide.]
[D07AC21, halobetasol, The risk or severity of electrolyte imbalance can be increased when Ulobetasol is combined with Bendroflumethiazide.]
[V03AF05, amifostine, Bendroflumethiazide may increase the hypotensive activities of Amifostine.]
[C01BD05, ibutilide, Bendroflumethiazide may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[N04AA05, profenamine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Profenamine.]
[N03AD01, ethosuximide, Bendroflumethiazide may increase the bradycardic activities of Ethosuximide.]
[M01AC06, meloxicam, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ethylmorphine.]
[C01CA01, etilefrine, Etilefrine may decrease the antihypertensive activities of Bendroflumethiazide.]
[N01AX07, etomidate, Bendroflumethiazide may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB01, etoposide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Etoposide.]
[L04AD02, tacrolimus, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Tacrolimus.]
[R06AX12, terfenadine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Terfenadine.]
[P01AX07, trimetrexate, Bendroflumethiazide may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Bendroflumethiazide may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, The risk or severity of hyponatremia can be increased when Fluvoxamine is combined with Bendroflumethiazide.]
[L02AE02, leuprolide, Bendroflumethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01CB01, gold sodium thiomalate, Bendroflumethiazide may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Bendroflumethiazide may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF02, dexrazoxane, Bendroflumethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Bendroflumethiazide may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA02, felodipine, The therapeutic efficacy of Felodipine can be increased when used in combination with Bendroflumethiazide.]
[C08EA01, fendiline, Bendroflumethiazide may increase the bradycardic activities of Fendiline.]
[M01AE04, fenoprofen, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypokalemia can be increased when Fenoterol is combined with Bendroflumethiazide.]
[N02AB03, fentanyl, Bendroflumethiazide may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, The risk or severity of hypokalemia can be increased when Salbutamol is combined with Bendroflumethiazide.]
[B01AD05, plasmin, The therapeutic efficacy of Fibrinolysin can be decreased when used in combination with Bendroflumethiazide.]
[L01BB06, clofarabine, Bendroflumethiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA40, cladribine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Cladribine.]
[N07AX03, cevimeline, Bendroflumethiazide may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Bendroflumethiazide may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Floctafenine.]
[J02AC01, fluconazole, Bendroflumethiazide may increase the excretion rate of Fluconazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AX01, flucytosine, Bendroflumethiazide may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA02, fludrocortisone, The risk or severity of electrolyte imbalance can be increased when Fludrocortisone is combined with Bendroflumethiazide.]
[V03AB25, flumazenil, Bendroflumethiazide may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XB01, flumethasone, The risk or severity of electrolyte imbalance can be increased when Flumethasone is combined with Bendroflumethiazide.]
[N07CA03, flunarizine, Bendroflumethiazide may increase the bradycardic activities of Flunarizine.]
[D07AC08, fluocinonide, The risk or severity of electrolyte imbalance can be increased when Fluocinonide is combined with Bendroflumethiazide.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Bendroflumethiazide.]
[H02AB03, fluocortolone, The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Bendroflumethiazide.]
[V03AZ01, ethanol, The risk or severity of hypotension and orthostatic hypotension can be increased when Ethanol is combined with Bendroflumethiazide.]
[L01BC09, floxuridine, Bendroflumethiazide may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01CB05, fluorometholone, The risk or severity of electrolyte imbalance can be increased when Fluorometholone is combined with Bendroflumethiazide.]
[L01BC02, fluorouracil, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Bendroflumethiazide.]
[N05AF01, flupenthixol, Flupentixol may decrease the antihypertensive activities of Bendroflumethiazide.]
[D07AC07, flurandrenolide, The risk or severity of electrolyte imbalance can be increased when Flurandrenolide is combined with Bendroflumethiazide.]
[N05CD01, flurazepam, Bendroflumethiazide may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Flurbiprofen.]
[N05AG01, fluspirilene, Bendroflumethiazide may increase the bradycardic activities of Fluspirilene.]
[L02BB01, flutamide, Bendroflumethiazide may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Bendroflumethiazide may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Bendroflumethiazide may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC03, tegafur, Bendroflumethiazide may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX17, adrafinil, Adrafinil may decrease the antihypertensive activities of Bendroflumethiazide.]
[M03AA01, alcuronium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Bendroflumethiazide.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be increased when used in combination with Bendroflumethiazide.]
[N05CF04, eszopiclone, Bendroflumethiazide may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DA04, galantamine, Bendroflumethiazide may increase the bradycardic activities of Galantamine.]
[M03AC02, gallamine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Gallamine.]
[C08DA02, gallopamil, Bendroflumethiazide may increase the bradycardic activities of Gallopamil.]
[S01AD09, ganciclovir, Bendroflumethiazide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, The risk or severity of hypotension and orthostatic hypotension can be increased when Barbexaclone is combined with Bendroflumethiazide.]
[C10AB04, gemfibrozil, Bendroflumethiazide may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Bendroflumethiazide may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA02, dasatinib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Dasatinib.]
[N04BC06, cabergoline, Cabergoline may decrease the antihypertensive activities of Bendroflumethiazide.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Bendroflumethiazide.]
[A12AA13, calcium citrate, Bendroflumethiazide may decrease the excretion rate of Calcium citrate which could result in a higher serum level.]
[A12AA10, calcium gluceptate, Bendroflumethiazide may decrease the excretion rate of Calcium glucoheptonate which could result in a higher serum level.]
[A12AA05, calcium lactate, Bendroflumethiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.]
[A12AA30, calcium levulinate, Bendroflumethiazide may decrease the excretion rate of Calcium levulinate which could result in a higher serum level.]
[N03AD03, methsuximide, Bendroflumethiazide may increase the bradycardic activities of Methsuximide.]
[N01AH02, alfentanil, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Alfentanil.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Bendroflumethiazide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Bendroflumethiazide.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Bendroflumethiazide.]
[N05CM18, dexmedetomidine, Bendroflumethiazide may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Glycerin.]
[C05AE01, nitroglycerin, The therapeutic efficacy of Nitroglycerin can be increased when used in combination with Bendroflumethiazide.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Bendroflumethiazide is combined with Dofetilide.]
[C02CA04, doxazosin, The therapeutic efficacy of Doxazosin can be increased when used in combination with Bendroflumethiazide.]
[L01EX02, sorafenib, Bendroflumethiazide may increase the excretion rate of Sorafenib which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB09, esmolol, The therapeutic efficacy of Esmolol can be increased when used in combination with Bendroflumethiazide.]
[M01CB04, aurothioglucose, Bendroflumethiazide may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Bendroflumethiazide may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be decreased when used in combination with Bendroflumethiazide.]
[C09AA09, fosinopril, The therapeutic efficacy of Fosinopril can be increased when used in combination with Bendroflumethiazide.]
[S01EX01, guanethidine, The therapeutic efficacy of Guanethidine can be increased when used in combination with Bendroflumethiazide.]
[L02AE03, goserelin, Bendroflumethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AD02, halcinonide, The risk or severity of electrolyte imbalance can be increased when Halcinonide is combined with Bendroflumethiazide.]
[N05AD01, haloperidol, Bendroflumethiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB01, halothane, Halothane may decrease the antihypertensive activities of Bendroflumethiazide.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Bendroflumethiazide.]
[N06BX13, idebenone, Bendroflumethiazide may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin aspart.]
[L01CE02, irinotecan, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Irinotecan.]
[M04AA01, allopurinol, The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Bendroflumethiazide.]
[C09CA01, losartan, The therapeutic efficacy of Losartan can be increased when used in combination with Bendroflumethiazide.]
[S01XA14, heparin, The therapeutic efficacy of Heparin can be decreased when used in combination with Bendroflumethiazide.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Magnesium citrate.]
[G03DC01, allylestrenol, Bendroflumethiazide may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mesalazine.]
[C01CE02, milrinone, Bendroflumethiazide may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sodium fluorophosphate.]
[L01XX03, altretamine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Altretamine.]
[N05CA16, hexobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Hexobarbital is combined with Bendroflumethiazide.]
[R03CC05, hexoprenaline, The risk or severity of hypokalemia can be increased when Hexoprenaline is combined with Bendroflumethiazide.]
[C08CA10, nilvadipine, The therapeutic efficacy of Nilvadipine can be increased when used in combination with Bendroflumethiazide.]
[M02AA26, nimesulide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nimesulide.]
[C09AA04, perindopril, The therapeutic efficacy of Perindopril can be increased when used in combination with Bendroflumethiazide.]
[C02DB02, hydralazine, The therapeutic efficacy of Hydralazine can be increased when used in combination with Bendroflumethiazide.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Hydrochlorothiazide can be increased when used in combination with Bendroflumethiazide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of electrolyte imbalance can be increased when Hydrocortisone is combined with Bendroflumethiazide.]
[D07AC16, hydrocortisone aceponate, The risk or severity of electrolyte imbalance can be increased when Hydrocortisone aceponate is combined with Bendroflumethiazide.]
[D07AB11, hydrocortisone probutate, The risk or severity of electrolyte imbalance can be increased when Hydrocortisone probutate is combined with Bendroflumethiazide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Hydroflumethiazide can be increased when used in combination with Bendroflumethiazide.]
[B05XA17, potassium acetate, Bendroflumethiazide may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Bendroflumethiazide may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Bendroflumethiazide may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA07, hetastarch, Bendroflumethiazide may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX05, hydroxyurea, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Hydroxyurea.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be increased when used in combination with Bendroflumethiazide.]
[S01BA13, rimexolone, The risk or severity of electrolyte imbalance can be increased when Rimexolone is combined with Bendroflumethiazide.]
[R02AX02, ibuprofen, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ibuprofen.]
[B05XA08, sodium acetate, Bendroflumethiazide may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05CB02, sodium citrate, The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Bendroflumethiazide.]
[L01DB06, idarubicin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Idarubicin.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sodium tartrate.]
[L01AA06, ifosfamide, Bendroflumethiazide may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AH03, sufentanil, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, Bendroflumethiazide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of electrolyte imbalance can be increased when Tixocortol is combined with Bendroflumethiazide.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tizanidine.]
[L01CE01, topotecan, Bendroflumethiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Bendroflumethiazide.]
[S01BC01, indomethacin, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Bendroflumethiazide.]
[C02CA02, indoramin, The therapeutic efficacy of Indoramin can be increased when used in combination with Bendroflumethiazide.]
[A11HA07, inositol, Bendroflumethiazide may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB04, interferon alfa-2a, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of hyponatremia can be increased when Milnacipran is combined with Bendroflumethiazide.]
[A03AA30, piperidolate, The serum concentration of Bendroflumethiazide can be increased when it is combined with Piperidolate.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cyclopentamine.]
[S01XA28, varenicline, Bendroflumethiazide may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Bendroflumethiazide.]
[N05BA12, alprazolam, Bendroflumethiazide may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Bendroflumethiazide may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AE01, buclizine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Buclizine.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Bendroflumethiazide.]
[C07AA01, alprenolol, The therapeutic efficacy of Alprenolol can be increased when used in combination with Bendroflumethiazide.]
[L03AB09, interferon alfacon-1, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfacon-1.]
[V03AB01, ipecac, Bendroflumethiazide may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Bendroflumethiazide.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Bendroflumethiazide.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Bendroflumethiazide.]
[S01EC03, dorzolamide, The therapeutic efficacy of Dorzolamide can be increased when used in combination with Bendroflumethiazide.]
[R03CC06, isoetharine, The risk or severity of hypokalemia can be increased when Isoetharine is combined with Bendroflumethiazide.]
[C09AA16, imidapril, The therapeutic efficacy of Imidapril can be increased when used in combination with Bendroflumethiazide.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Bendroflumethiazide.]
[J04AC01, isoniazid, Bendroflumethiazide may increase the excretion rate of Isoniazid which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AX05, inosine pranobex, Bendroflumethiazide may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB01, isoproterenol, The risk or severity of hypokalemia can be increased when Isoprenaline is combined with Bendroflumethiazide.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Bendroflumethiazide.]
[C01DA14, isosorbide mononitrate, Bendroflumethiazide may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, Bendroflumethiazide may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, Isoxsuprine may decrease the antihypertensive activities of Bendroflumethiazide.]
[B01AE06, bivalirudin, The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Bendroflumethiazide.]
[N01AX03, ketamine, Bendroflumethiazide may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KD01, ketanserin, The therapeutic efficacy of Ketanserin can be increased when used in combination with Bendroflumethiazide.]
[B01AC22, prasugrel, Bendroflumethiazide may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH03, olanzapine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bendroflumethiazide.]
[C01CA22, arbutamine, The risk or severity of hypokalemia can be increased when Arbutamine is combined with Bendroflumethiazide.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Bendroflumethiazide.]
[D10AX03, azelaic acid, Bendroflumethiazide may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tiaprofenic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Labetalol can be increased when used in combination with Bendroflumethiazide.]
[N04BB01, amantadine, Bendroflumethiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA05, deserpidine, The therapeutic efficacy of Deserpidine can be increased when used in combination with Bendroflumethiazide.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Lubiprostone.]
[N03AX18, lacosamide, Bendroflumethiazide may increase the bradycardic activities of Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Etacrynic acid.]
[L01DC03, mitomycin, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Mitomycin.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Bendroflumethiazide is combined with Levodopa.]
[C08EX01, lidoflazine, Bendroflumethiazide may increase the bradycardic activities of Lidoflazine.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Amiloride.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Bendroflumethiazide.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L01AD02, lomustine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Lomustine.]
[A07DA03, loperamide, Bendroflumethiazide may increase the bradycardic activities of Loperamide.]
[A12AA11, calcium pangamate, Bendroflumethiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.]
[N05BA06, lorazepam, Bendroflumethiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EG01, temsirolimus, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Bendroflumethiazide may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Bendroflumethiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA03, nilotinib, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mannitol.]
[N06AA21, maprotiline, Bendroflumethiazide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, The therapeutic efficacy of Mecamylamine can be increased when used in combination with Bendroflumethiazide.]
[L01AA05, mechlorethamine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Mechlorethamine.]
[R06AE05, meclizine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Meclizine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meclofenamic acid.]
[C01AA08, medigoxin, Bendroflumethiazide may increase the hypokalemic activities of Metildigoxin.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Frangula purshiana bark.]
[B01AB06, nadroparin, The therapeutic efficacy of Nadroparin can be decreased when used in combination with Bendroflumethiazide.]
[B01AB05, enoxaparin, The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Bendroflumethiazide.]
[B01AB04, dalteparin, The therapeutic efficacy of Dalteparin can be decreased when used in combination with Bendroflumethiazide.]
[L01AA03, melphalan, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Melphalan.]
[N06DX01, memantine, Bendroflumethiazide may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Bendroflumethiazide may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA11, mephentermine, Mephentermine may decrease the antihypertensive activities of Bendroflumethiazide.]
[N03AA01, mephobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Methylphenobarbital is combined with Bendroflumethiazide.]
[N01BB03, mepivacaine, Bendroflumethiazide may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Bendroflumethiazide may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, Bendroflumethiazide may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Bendroflumethiazide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA09, metaraminol, Metaraminol may decrease the antihypertensive activities of Bendroflumethiazide.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide.]
[H01CB03, lanreotide, Bendroflumethiazide may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, Bendroflumethiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Bendroflumethiazide may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB07, methantheline, The serum concentration of Bendroflumethiazide can be increased when it is combined with Methantheline.]
[J05AF05, lamivudine, Bendroflumethiazide may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA30, metharbital, The serum concentration of Bendroflumethiazide can be increased when it is combined with Metharbital.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Methazolamide.]
[J01XX05, methenamine, The therapeutic efficacy of Methenamine can be decreased when used in combination with Bendroflumethiazide.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Bendroflumethiazide.]
[H03BB02, methimazole, Bendroflumethiazide may increase the excretion rate of Methimazole which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BA04, pemetrexed, Bendroflumethiazide may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA15, methohexital, The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Bendroflumethiazide.]
[A11HA02, pyridoxine, Bendroflumethiazide may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Bendroflumethiazide is combined with Ziconotide.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Methotrexate.]
[N05AA02, methotrimeprazine, Methotrimeprazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[C01CA10, methoxamine, Methoxamine may decrease the antihypertensive activities of Bendroflumethiazide.]
[D05BA02, methoxsalen, Bendroflumethiazide may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG09, methoxyflurane, Methoxyflurane may decrease the antihypertensive activities of Bendroflumethiazide.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Bendroflumethiazide can be increased when used in combination with Methyclothiazide.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Methylcellulose.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be increased when used in combination with Bendroflumethiazide.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Bendroflumethiazide.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Bendroflumethiazide.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.]
[H02AB04, methylprednisolone, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Bendroflumethiazide.]
[D07AC14, methylprednisolone aceponate, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Bendroflumethiazide.]
[G03EK01, methyltestosterone, Bendroflumethiazide may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA04, methysergide, Methysergide may decrease the antihypertensive activities of Bendroflumethiazide.]
[A03FA01, metoclopramide, Bendroflumethiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, The therapeutic efficacy of Metolazone can be increased when used in combination with Bendroflumethiazide.]
[C07AB02, metoprolol, The therapeutic efficacy of Metoprolol can be increased when used in combination with Bendroflumethiazide.]
[V04CD01, metyrapone, Bendroflumethiazide may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Bendroflumethiazide.]
[N02BB03, aminopyrine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Aminophenazone.]
[B01AB07, parnaparin, The therapeutic efficacy of Parnaparin can be decreased when used in combination with Bendroflumethiazide.]
[N05CD08, midazolam, Bendroflumethiazide may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA17, midodrine, Midodrine may decrease the antihypertensive activities of Bendroflumethiazide.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Bendroflumethiazide.]
[B01AB10, tinzaparin, The therapeutic efficacy of Tinzaparin can be decreased when used in combination with Bendroflumethiazide.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mineral oil.]
[J05AH01, zanamivir, Bendroflumethiazide may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The therapeutic efficacy of Valsartan can be increased when used in combination with Bendroflumethiazide.]
[D11AX01, minoxidil, The therapeutic efficacy of Minoxidil can be increased when used in combination with Bendroflumethiazide.]
[L01DB07, mitoxantrone, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Mitoxantrone.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L03AC01, aldesleukin, Bendroflumethiazide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Bendroflumethiazide.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Amiodarone.]
[N06AA09, amitriptyline, Bendroflumethiazide may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA01, morphine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Morphine.]
[A04AA05, palonosetron, Bendroflumethiazide may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB05, certolizumab pegol, Bendroflumethiazide may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BA01, ammonium chloride, Bendroflumethiazide may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA06, mycophenolic acid, Bendroflumethiazide may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC03, vecuronium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Amobarbital is combined with Bendroflumethiazide.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Bendroflumethiazide is combined with Silodosin.]
[R03BB01, ipratropium bromide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium.]
[N06AA17, amoxapine, Amoxapine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L03AB08, interferon beta-1b, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon beta-1b.]
[J01CA04, amoxicillin, Bendroflumethiazide may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Bendroflumethiazide.]
[N02AF02, nalbuphine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, Bendroflumethiazide may increase the excretion rate of Naloxone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BB04, naltrexone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naltrexone.]
[S01GA01, naphazoline, Naphazoline may decrease the antihypertensive activities of Bendroflumethiazide.]
[N06BA01, amphetamine, Bendroflumethiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The therapeutic efficacy of Naproxen can be decreased when used in combination with Bendroflumethiazide.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Bendroflumethiazide.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Bendroflumethiazide is combined with Duloxetine.]
[N04BX01, tolcapone, Bendroflumethiazide may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD02, docetaxel, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Docetaxel.]
[N01AH06, remifentanil, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Bendroflumethiazide.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Levosimendan.]
[B01AC17, tirofiban, Bendroflumethiazide may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX14, iloperidone, Iloperidone may decrease the antihypertensive activities of Bendroflumethiazide.]
[J02AA01, amphotericin B, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Bendroflumethiazide.]
[S01AA19, ampicillin, Bendroflumethiazide may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Bendroflumethiazide may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX23, desvenlafaxine, The risk or severity of hyponatremia can be increased when Desvenlafaxine is combined with Bendroflumethiazide.]
[C09CA07, telmisartan, The therapeutic efficacy of Telmisartan can be increased when used in combination with Bendroflumethiazide.]
[J05AB11, valacyclovir, Bendroflumethiazide may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[M04AA03, febuxostat, The therapeutic efficacy of Febuxostat can be decreased when used in combination with Bendroflumethiazide.]
[H05BX02, paricalcitol, The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Paricalcitol.]
[C01CE01, inamrinone, Bendroflumethiazide may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX01, amsacrine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Amsacrine.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Bendroflumethiazide.]
[C08CA04, nicardipine, The therapeutic efficacy of Nicardipine can be increased when used in combination with Bendroflumethiazide.]
[C04AE02, nicergoline, Nicergoline may decrease the antihypertensive activities of Bendroflumethiazide.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nicotine.]
[C08CA05, nifedipine, Bendroflumethiazide may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The therapeutic efficacy of Nimodipine can be increased when used in combination with Bendroflumethiazide.]
[C08CA07, nisoldipine, The therapeutic efficacy of Nisoldipine can be increased when used in combination with Bendroflumethiazide.]
[C08CA08, nitrendipine, The therapeutic efficacy of Nitrendipine can be increased when used in combination with Bendroflumethiazide.]
[R07AX01, nitric oxide, Bendroflumethiazide may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Bendroflumethiazide may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Bendroflumethiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Bendroflumethiazide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, The therapeutic efficacy of Nitroprusside can be increased when used in combination with Bendroflumethiazide.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Bendroflumethiazide.]
[C01CA03, norepinephrine, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Bendroflumethiazide.]
[C02KX01, bosentan, The therapeutic efficacy of Bosentan can be increased when used in combination with Bendroflumethiazide.]
[N06AA10, nortriptyline, Nortriptyline may decrease the antihypertensive activities of Bendroflumethiazide.]
[G02CA02, nylidrin, Nylidrin may decrease the antihypertensive activities of Bendroflumethiazide.]
[B01AB08, reviparin, The therapeutic efficacy of Reviparin can be decreased when used in combination with Bendroflumethiazide.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Bendroflumethiazide.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Bendroflumethiazide.]
[N02AA02, opium, Bendroflumethiazide may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB03, metaproterenol, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Bendroflumethiazide.]
[B01AD07, reteplase, The therapeutic efficacy of Reteplase can be decreased when used in combination with Bendroflumethiazide.]
[B01AD09, ancrod, The therapeutic efficacy of Ancrod can be decreased when used in combination with Bendroflumethiazide.]
[G04CA02, tamsulosin, Bendroflumethiazide may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AC01, ouabain, Bendroflumethiazide may increase the hypokalemic activities of Ouabain.]
[J01CF04, oxacillin, Bendroflumethiazide may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA04, oxazepam, Bendroflumethiazide may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA02, oxprenolol, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Bendroflumethiazide.]
[N02AA05, oxycodone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxycodone.]
[C01DX03, oxyfedrine, Oxyfedrine may decrease the antihypertensive activities of Bendroflumethiazide.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxymetazoline.]
[N02AA11, oxymorphone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Oxyphenonium.]
[N05AH05, asenapine, Asenapine may decrease the antihypertensive activities of Bendroflumethiazide.]
[B01AB09, danaparoid, The therapeutic efficacy of Danaparoid can be decreased when used in combination with Bendroflumethiazide.]
[N02AX06, tapentadol, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tapentadol.]
[M03AC01, pancuronium, The serum concentration of Bendroflumethiazide can be increased when it is combined with Pancuronium.]
[J04AB30, capreomycin, Bendroflumethiazide may increase the excretion rate of Capreomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of electrolyte imbalance can be increased when Paramethasone is combined with Bendroflumethiazide.]
[C02KC01, pargyline, The therapeutic efficacy of Pargyline can be increased when used in combination with Bendroflumethiazide.]
[G04BD11, fesoterodine, Bendroflumethiazide may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, The therapeutic efficacy of Penbutolol can be increased when used in combination with Bendroflumethiazide.]
[N05AG03, penfluridol, Bendroflumethiazide may increase the bradycardic activities of Penfluridol.]
[M01CC01, penicillamine, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Bendroflumethiazide may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA14, penicillin G, Bendroflumethiazide may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Pentobarbital is combined with Bendroflumethiazide.]
[L01XX08, pentostatin, Bendroflumethiazide may increase the excretion rate of Pentostatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Bendroflumethiazide.]
[N04BC02, pergolide, Pergolide may decrease the antihypertensive activities of Bendroflumethiazide.]
[C08EX02, perhexiline, Bendroflumethiazide may increase the bradycardic activities of Perhexiline.]
[N02AD02, phenazocine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, Bendroflumethiazide may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Bendroflumethiazide.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Bendroflumethiazide.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be decreased when used in combination with Bendroflumethiazide.]
[N03AA02, phenobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Bendroflumethiazide.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Phenoxybenzamine can be increased when used in combination with Bendroflumethiazide.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Bendroflumethiazide.]
[A08AA01, phentermine, Phentermine may decrease the antihypertensive activities of Bendroflumethiazide.]
[V03AB36, phentolamine, The therapeutic efficacy of Phentolamine can be increased when used in combination with Bendroflumethiazide.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Phenylbutazone.]
[S01GA05, phenylephrine, Phenylephrine may decrease the antihypertensive activities of Bendroflumethiazide.]
[R01BA01, phenylpropanolamine, The risk or severity of hypokalemia can be increased when Phenylpropanolamine is combined with Bendroflumethiazide.]
[S01AE05, levofloxacin, Bendroflumethiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BA01, vitamin K1, Bendroflumethiazide may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, Bendroflumethiazide may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CX01, mibefradil, The therapeutic efficacy of Mibefradil can be increased when used in combination with Bendroflumethiazide.]
[C07AA03, pindolol, The therapeutic efficacy of Pindolol can be increased when used in combination with Bendroflumethiazide.]
[J01CA12, piperacillin, Bendroflumethiazide may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX03, piracetam, Bendroflumethiazide may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The therapeutic efficacy of Eprosartan can be increased when used in combination with Bendroflumethiazide.]
[A02BX03, pirenzepine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Pirenzepine.]
[N02AC03, pirinitramide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Piroxicam.]
[N02CX01, pizotyline, Pizotifen may decrease the antihypertensive activities of Bendroflumethiazide.]
[C09CA04, irbesartan, The therapeutic efficacy of Irbesartan can be increased when used in combination with Bendroflumethiazide.]
[B01AC13, abciximab, The therapeutic efficacy of Abciximab can be decreased when used in combination with Bendroflumethiazide.]
[S01XA13, alteplase, The therapeutic efficacy of Alteplase can be decreased when used in combination with Bendroflumethiazide.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Bendroflumethiazide.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Polyethylene glycol.]
[C03AA05, polythiazide, The therapeutic efficacy of Polythiazide can be increased when used in combination with Bendroflumethiazide.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Bendroflumethiazide.]
[B05XA01, potassium chloride, Bendroflumethiazide may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin lispro.]
[C07AB01, practolol, The therapeutic efficacy of Practolol can be increased when used in combination with Bendroflumethiazide.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Bendroflumethiazide.]
[S03BA02, prednisolone, The risk or severity of electrolyte imbalance can be increased when Prednisolone is combined with Bendroflumethiazide.]
[H02AB07, prednisone, The risk or severity of electrolyte imbalance can be increased when Prednisone is combined with Bendroflumethiazide.]
[C01DX02, prenylamine, Bendroflumethiazide may increase the bradycardic activities of Prenylamine.]
[N03AA03, primidone, The risk or severity of hypotension and orthostatic hypotension can be increased when Primidone is combined with Bendroflumethiazide.]
[M04AB01, probenecid, The therapeutic efficacy of Probenecid can be decreased when used in combination with Bendroflumethiazide.]
[C01BA02, procainamide, Bendroflumethiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Bendroflumethiazide.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Bendroflumethiazide.]
[C10AB05, fenofibrate, Bendroflumethiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[N04AA04, procyclidine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Procyclidine.]
[N05AA03, promazine, Promazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[R06AD02, promethazine, Bendroflumethiazide may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC03, propafenone, Propafenone may decrease the antihypertensive activities of Bendroflumethiazide.]
[A03AB05, propantheline, Bendroflumethiazide may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC01, periciazine, Periciazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[N05CM06, propiomazine, Propiomazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[N01AX10, propofol, Propofol may decrease the antihypertensive activities of Bendroflumethiazide.]
[N02AC04, propoxyphene, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, The therapeutic efficacy of Propranolol can be increased when used in combination with Bendroflumethiazide.]
[H03BA02, propylthiouracil, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Propylthiouracil.]
[C01AB01, proscillaridin, Bendroflumethiazide may increase the hypokalemic activities of Proscillaridin.]
[N02CC04, rizatriptan, Bendroflumethiazide may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Bendroflumethiazide.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Bendroflumethiazide.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the antihypertensive activities of Bendroflumethiazide.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Bendroflumethiazide.]
[N07XX07, dalfampridine, Bendroflumethiazide may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB15, diphemanil, The serum concentration of Bendroflumethiazide can be increased when it is combined with Diphemanil.]
[A03AB09, isopropamide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Isopropamide.]
[S01FA03, methscopolamine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Methscopolamine.]
[N05CA07, talbutal, The serum concentration of Bendroflumethiazide can be increased when it is combined with Talbutal.]
[P02CC01, pyrantel, Bendroflumethiazide may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Bendroflumethiazide may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA01, quinidine, Bendroflumethiazide may increase the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Bendroflumethiazide.]
[D07AC10, diflorasone, The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Bendroflumethiazide.]
[A02BA02, ranitidine, Bendroflumethiazide may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, The therapeutic efficacy of Rescinnamine can be increased when used in combination with Bendroflumethiazide.]
[C02AA02, reserpine, The therapeutic efficacy of Reserpine can be increased when used in combination with Bendroflumethiazide.]
[J05AP01, ribavirin, Bendroflumethiazide may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC05, rimiterol, Rimiterol may decrease the antihypertensive activities of Bendroflumethiazide.]
[G02CA01, ritodrine, The risk or severity of hypokalemia can be increased when Ritodrine is combined with Bendroflumethiazide.]
[N02BA05, salicylamide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylic acid.]
[S01FA02, scopolamine, The serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.]
[N05CA06, secobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Secobarbital is combined with Bendroflumethiazide.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Bendroflumethiazide.]
[L01FA03, obinutuzumab, Bendroflumethiazide may increase the hypotensive activities of Obinutuzumab.]
[A12CD01, sodium fluoride, Bendroflumethiazide may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sotalol.]
[L01CD04, cabazitaxel, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Cabazitaxel.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Bendroflumethiazide.]
[D07AB02, hydrocortisone butyrate, The risk or severity of electrolyte imbalance can be increased when Hydrocortisone butyrate is combined with Bendroflumethiazide.]
